Form 4: Design Therapeutics Grants CAO 150,000 Stock Options

Design Therapeutics, Inc. granted 150,000 stock options to Chief Accounting Officer Julie Burgess with an exercise price of $9.10 and a multi-year vesting schedule.

Summary

• Julie Burgess, Chief Accounting Officer of Design Therapeutics, Inc. (DSGN), was granted 150,000 stock options.
• The options have an exercise price of $9.10 per share.
• The grant date for these options was January 2, 2026.
• The options will vest over several years: 20% on January 1, 2027; an additional 20% in equal monthly installments over the 12 months following January 1, 2027; 30% in equal monthly installments over the 12 months following that period; and the final 30% in equal monthly installments over the subsequent 12 months.
• The stock options are set to expire on January 1, 2036.
• Following this transaction, Julie Burgess beneficially owns 150,000 derivative securities directly.

Sentiment

Score: 6

Explanation: The grant of stock options to a key executive is generally viewed as a positive for aligning management incentives with shareholder interests, promoting long-term retention and performance. It is a routine compensation disclosure.

Positives

• The grant of stock options aligns the Chief Accounting Officer's financial interests with the long-term performance and shareholder value of Design Therapeutics, Inc.
• This compensation structure can serve as an incentive for executive retention and sustained performance over the multi-year vesting period.

Future Outlook

The multi-year vesting schedule for the stock options, extending through January 2029, indicates a long-term commitment for the Chief Accounting Officer and aims to incentivize sustained performance and value creation over this period.

Industry Context

The grant of stock options is a common practice in the biotechnology and pharmaceutical industries, particularly for growth-oriented companies, as a key component of executive compensation packages designed to attract, retain, and motivate talent by aligning their financial success with the company's long-term share price performance.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the biotechnology and pharmaceutical sectors, aiming to align management incentives with long-term shareholder value.
• This grant is consistent with typical compensation structures for key officers in publicly traded companies, though specific comparisons to other companies' grant sizes would require additional context not provided in this filing.

Stakeholder Impact

• Shareholders: The option grant aims to align the Chief Accounting Officer's interests with shareholder value creation, potentially leading to improved long-term performance.
• Employees: This grant is part of the executive compensation strategy, which can influence overall compensation philosophy and morale within the company.

Next Steps

• The stock options will vest according to the specified schedule, with the first tranche vesting on January 1, 2027, and subsequent tranches vesting monthly over the following three years.
• The Chief Accounting Officer may exercise vested options at the specified exercise price before the expiration date of January 1, 2036.

Key Dates

Keywords

DSGN, Design Therapeutics, stock option, executive compensation, insider transaction, Form 4, Julie Burgess